Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice

Chmielewska, Joanna; Poggi, Andreina; Mussoni, L.; Donati, Maria Benedetta; Garattini, Silvio

doi:10.1016/0014-2964(80)90048-1

Cited by 20 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in fibrinogen level observed in mFS6 appears to be due more to an acute-phase reaction than to a synthetic response in low-grade intravascular clotting. This contention is indirectly supported by the fact that hyperfibrinogenaemia has been reported in several rat and murine tumours, in association with either increased or normal fibrinogen turnover (Hilgard et al, 1973;Poggi et al, 1977;Chmielewska et al, 1980) and with different patterns of fibrin deposition around the tumour. That thrombocytopenia and hyperfibrinogenaemia, at least in the 3LL model, were not due to consumption coagulopathy is further indicated by the fact that they were not corrected by anticoagulants or platelet aggregation inhibitors given chronically to tumour-bearing mice .…”

Section: Figurementioning

confidence: 92%

“…In the JW sarcoma, thrombocytopenia was not accompanied by any signs of intravascular coagulation (Chmielewska et al, 1980). The increase in fibrinogen level observed in mFS6 appears to be due more to an acute-phase reaction than to a synthetic response in low-grade intravascular clotting.…”

Section: Figurementioning

confidence: 97%

“…These changes appeared during the period of lung metastatic growth after i.m. im- plantation of tumour cells (Poggi et al, 1977;Chmielewska et al, 1980) but it is not yet clearly established whether the metastases are indeed responsible for them.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host

Delaini¹,

Giavazzi²,

Vitti³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

Summary.-This paper is aimed at investigating how metastatic tumour growth influenced the haemostatic system of the host. Blood platelet count, blood fibrinogen level, the activated partial thromboplastin time (APTT) and the prothrombin time (PT) were determined at various intervals during growth and metastasis of a murine fibrosarcoma (mFS6) or one of its sublines with different metastatic capacity. Progressive thrombocytopenia and increase in fibrinogen level were observed during development of the tumour in all the animal groups studied, irrespective of the metastatic potential of the various sublines. No significant changes were observed in the PT or APTT values. These data support the concept that primary rather than metastatic growth influences the haemostatic system of tumour-bearing animals.

show abstract

Section: Figurementioning

confidence: 92%

Section: Figurementioning

confidence: 97%

See 1 more Smart Citation

Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host

Delaini¹,

Giavazzi²,

Vitti³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Of particular relevance to this discussion is the observation that warfarin treatment pre vented metastatic growth just in the 3 murine tumors (3LL, B16 melanoma and JW sarco ma) where a procoagulant with the character istics of CP has been identified both biochem ically and immunologically [7,12,15,26].…”

Section: A Vitamin K-dependent Procoagulant In Cancer Cellsmentioning

confidence: 99%

“…In this model, the growth of the primary tumor and the appearance of lung metastases are accompanied by alterations of the host's hemostatic system which can be monitored by laboratory tests and reveal thrombocyto penia (due to decreased platelet production), increased fibrinogen level and, in some in stances, activation of the blood-clotting sys tem [6][7][8][9].…”

Section: Anticoagulation and Tumor Metastasismentioning

confidence: 99%

Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin?

Donati

Roncaglioni

Falanga

et al. 1986

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

Anticoagulants of the coumarin type have long been reported to inhibit metastasis growth in experimental animals; however, the mechanisms of such effects has not been clarified. Systemic anticoagulation per se does not appear to account completely for such metastasis growth depression. More recent information gathered on a cell procoagulant activity, which is vitamin K-dependent, could probably supply a fresh insight into this problem. Indeed, vitamin K deficiency induced either dietarily or pharmacologically by warfarin, does inhibit the activity of a cysteine protease with direct factor-X-activating properties. This protease is only present in warfarin-sensitive tumors. The correlation of this activity with cancer cell invasiveness is supported by experimental data in metastatic variants and, lately, also by the observation of markedly higher cancer procoagulant activity in extracts from metastases than from primary human melanomas.

show abstract

Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics

Falanga

Dalessandro

Casali

et al. 1987

Intl Journal of Cancer

View full text Add to dashboard Cite

Cancer Procoagulant (CP), a cysteine proteinase which triggers blood coagulation by directly activating Factor X (FX) in the absence of Factor VII (F VII), has recently been isolated from rabbit V2 carcinoma and biochemically characterized. We have studied the procoagulant activity of tissue extracts from 4 murine experimental tumors in order to define whether or not a F VII-independent activity with cysteine proteinase characteristics was present. The tumors studied were: Lewis lung carcinoma (3LL), B16 melanoma (B16), JW sarcoma (JWS) and the M4 variant of the mFS6 fibrosarcoma (M4). Extracts from 3LL, B16 and JWS tumor initiated coagulation in both the presence and absence of F VII, their procoagulant activity was sensitive to iodoacetamide (1 mM) and mercury chloride (0.1 mM). The procoagulant of M4 extract was dependent on the presence of F VII and was not significantly affected by the cysteine proteinase inhibitors. An Ouchterlony double immunodiffusion study showed immunological cross-reactivity of all but M4 extracts to a polyclonal antibody to purified CP. The present study suggests that the procoagulant(s) present in the murine tumors 3LL, B16 and JWS are enzymatically and immunologically indistinguishable from cancer procoagulant of the rabbit V2 carcinoma.

show abstract

Blood coagulation changes in JW sarcoma, a new metastasizing tumour in mice

Cited by 20 publications

References 26 publications

Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host

Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host

Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin?

Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics

Contact Info

Product

Resources

About